Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia

3 Jun 2014

Abstract excerpt

Hypomethylating agents are widely used in patients with myelodysplastic syndromes and unfit patients with acute myeloid leukemia. However, it is not well understood why only some patients respond to hypomethylating agents. We found previously that the effect of decitabine on hematopoietic stem cell viability differed between Mll5 wild-type and null cells. We, therefore, investigated the role of MLL5 expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24895338
DOI: 10.3324/haematol.2013.101386

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemiaPMID 24895338Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Evolution of decitabine developmentSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemiaSemantic proximity Read ↗

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.Semantic proximity Read ↗

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Identification and validation of prognosis‐related DLX5 methylation as an epigenetic driver in myeloid neoplasmsSemantic proximity Read ↗

Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation.Semantic proximity Read ↗

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaSemantic proximity Read ↗

Dissection of demethylation and toxicity induced gene expression changes after decitabine treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.